portfolio strategy
BioMarin Plans to Divest Hemophilia Gene Therapy Roctavian Amid Strategic Refocus
BioMarin; Roctavian; hemophilia A; gene therapy; divestment; out-licensing; portfolio strategy; third quarter 2025; revenue challenge
How Science Drives Better Business Decisions in Biopharma (2025 Update)
biopharma; decision science; AI; digital twins; R&D; portfolio strategy; data-driven decisions; innovation; business strategy